Comparison of bronchial responsiveness to histamine in asthma, allergic rhinitis and allergic sensitization at the age of 7 years
Article first published online: 6 SEP 2002
Clinical & Experimental Allergy
Volume 32, Issue 9, pages 1274–1277, September 2002
How to Cite
Nickel, R., Lau, S., Niggemann, B., Sommerfeld, C., Wahn, U. and the German Multicenter Allergy Study Group (2002), Comparison of bronchial responsiveness to histamine in asthma, allergic rhinitis and allergic sensitization at the age of 7 years. Clinical & Experimental Allergy, 32: 1274–1277. doi: 10.1046/j.1365-2745.2002.01482.x
- Issue published online: 6 SEP 2002
- Article first published online: 6 SEP 2002
- Submitted 18 January 2002; revised 25 April 2002; accepted 12 June 2002
- allergic rhinitis;
Background Bronchial responsiveness (BR) to histamine or methacholin is a common finding in adult non-asthmatic patients with allergic rhinitis.
Objective We tested whether BR is also present in children with a comparatively short history of allergic rhinitis in a paediatric cohort.
Methods We performed pulmonary function tests and histamine challenges in a total of 654 children (age 7 years, participants of the German Multicenter Allergy Study) and compared PC20 FEV1 values in children with asthma, allergic rhinitis, asymptomatic allergic sensitization and non-atopic controls.
Results Most pronounced BR to histamine was observed in allergic asthmatics (n = 28), irrespective of the presence or absence of allergic rhinitis. Furthermore, PC20FEV1 values in non-asthmatic children with allergic rhinitis (n = 24) were not significantly different from those seen in asymptomatic atopic (n = 54) or non-atopic controls (n = 92).
Conclusions In contrast to adult study populations, 7-year-old non-asthmatic children with allergic rhinitis do not show a higher degree of BR than asymptomatic atopic or non-atopic controls. Therefore, secondary preventive measures in non-asthmatic children with allergic rhinitis (such as regular local anti-inflammatory therapy or specific immunotherapy) should be studied and applied more intensely to prevent bronchial hyper-responsiveness (BHR) and asthma in this high-risk group.